Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902907 | 1.00 | HTR6 (0.46) | HTR6NAMPTKDM4CKDM6BDRD2 | |
| SCHEMBL17361995 | 0.85 | HTR6 (0.48) | HTR6DRD2 | |
| SCHEMBL17378765 | 0.81 | HTR6 (0.46) | HTR6KDM4CKDM6B | |
| SCHEMBL316505 | 0.80 | KDM4C (0.56) | HTR6KDM4C | |
| SCHEMBL22744715 | 0.80 | KDM4C (0.57) | KDM4CKDM6B | |
| SCHEMBL17362072 | 0.80 | KDM4C (0.57) | KDM4CKDM6B | |
| SCHEMBL17361636 | 0.79 | HTR6 (0.49) | HTR6DRD2 | |
| SCHEMBL316011 | 0.79 | HTR6 (0.49) | HTR6DRD2 | |
| SCHEMBL316172 | 0.79 | HTR6 (0.49) | HTR6DRD2 | |
| SCHEMBL316010 | 0.79 | HTR6 (0.49) | HTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | HTR6 1/4885NAMPT 2481/4885KDM4C 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.